Search

Your search keyword '"Finetti, Pascal"' showing total 8 results
Start Over Author "Finetti, Pascal" Journal oncoimmunology
8 results on '"Finetti, Pascal"'

1. Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors

Author

Bertucci, François, primary, Boudin, Laurys, additional, Finetti, Pascal, additional, Van Berckelaer, Christophe, additional, Van Dam, Peter, additional, Dirix, Luc, additional, Viens, Patrice, additional, Gonçalves, Anthony, additional, Ueno, Naoto T., additional, Van Laere, Steven, additional, Birnbaum, Daniel, additional, and Mamessier, Emilie, additional

Published
2021
Full Text
View/download PDF

3. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas

Author

Bertucci, François, primary, Finetti, Pascal, additional, Perrot, Delphine, additional, Leroux, Agnès, additional, Collin, Françoise, additional, Le Cesne, Axel, additional, Coindre, Jean-Michel, additional, Blay, Jean-Yves, additional, Birnbaum, Daniel, additional, and Mamessier, Emilie, additional

Published
2017
Full Text
View/download PDF

4. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

Author

Hendrickx, Wouter, primary, Simeone, Ines, additional, Anjum, Samreen, additional, Mokrab, Younes, additional, Bertucci, François, additional, Finetti, Pascal, additional, Curigliano, Giuseppe, additional, Seliger, Barbara, additional, Cerulo, Luigi, additional, Tomei, Sara, additional, Delogu, Lucia Gemma, additional, Maccalli, Cristina, additional, Wang, Ena, additional, Miller, Lance D., additional, Marincola, Francesco M., additional, Ceccarelli, Michele, additional, and Bedognetti, Davide, additional

Published
2017
Full Text
View/download PDF

7. PDL1expression is associated with longer postoperative, survival in adrenocortical carcinoma

Author

Billon, Emilien, Finetti, Pascal, Bertucci, Alexandre, Niccoli, Patricia, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François

Abstract

ABSTRACTAdrenocortical carcinomas (ACCs) are heterogeneous cancers associated with a very poor prognosis. The improvement of prognostic tools and systemic therapy are urgently needed. Targeting the immune system using checkpoint inhibitors such as PD1/PDL1 inhibitors is an attractive novel therapeutic strategy for poor-prognosis tumors. Multiple clinical trials are ongoing, including in advanced ACC. However, PDL1 expression has been studied in ACC in only one heterogeneous series of 28 clinical samples. Here, we have retrospectively analyzed PDL1mRNA expression in 146 clinical ACC samples and searched for correlations between expression and biological and clinicopathological data, including post-operative disease-free survival (DFS). PDL1mRNA expression was heterogeneous across samples. “PDL1-high” tumors were not associated with the classical prognostic variables but were associated with longer DFS in both uni- and multivariate analyses. High PDL1 mRNA expression was associated with biological signs of the cytotoxic local immune response. Supervised analysis between “PDL1-high” and “PDL1-low” tumors identified a robust 370-gene signature whose ontology analysis suggested the existence in “PDL1-high” tumors of a cytotoxic T-cell response, however, associated with some degree of T-cell exhaustion. In conclusion, PDL1mRNA expression refines the prognostication in ACC and high expression is associated with longer DFS. Clinical validation at the protein level and functional validation are required to fully understand the role of PDL1 in ACC. Reactivation of dormant tumor-infiltrating lymphocytes by PDL1-inhibitors could represent a promising strategy in “PDL1-high” ACCs, supporting the ongoing clinical trials.

Published
2019
Full Text
View/download PDF

8. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

Author

Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, and Mamessier, Emilie

Subjects
*BREAST cancer treatment, *MESSENGER RNA, *IMMUNE response, *CANCER chemotherapy, *LYMPHOCYTES
Abstract

Analysis ofPDL1mRNA expression in ∼5,500 breast cancers showedPDL1upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results